Drug intelligence / Profile preview

SKINCURE

Development stage: Preclinical
Lead developer: Syngulon
Modality: Peptides
Administration: Topical

Overview

SKINCURE is an antimicrobial peptide program developed by Syngulon, a synthetic biology company. The program focuses on the use of bacteriocins—ribosomally synthesized peptides produced by bacteria—to treat skin pathogenic bacterial infections. These bacteriocins are engineered to provide targeted antibacterial activity, often by disrupting the integrity of the bacterial cell membrane or interfering with essential metabolic pathways, offering a potential solution to address antimicrobial resistance in dermatological applications.

Beyond the preview

Go deeper on SKINCURE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKINCURE.

Explore the full profile